A Phase II study of the safety, pharmacokinetics and efficacy of InceITM (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC)

被引：0
|
作者：
Einstein, A
Lush, R
Rago, R
Bubley, G
Henner, WD
Chatta, G
Shepard, R
Merica, EA
Harding, MW
Dalton, WS
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Beth Israel Deaconess Hosp, Boston, MA USA
[3] Oregon Hlth Sci Univ, Portland, OR 97201 USA
[4] Arkansas Canc Res Ctr, Little Rock, AR USA
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81827-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1411
引用
收藏
页码：S349 / S349
页数：1
相关论文
共 50 条
  • [1] A Phase II study of the safety, pharmacokinetics and efficacy of Incel™ (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in hormone refractory prostate cancer (HRPC).
    Einstein, A
    Lush, R
    Rago, R
    Ko, YJ
    Bubley, G
    Henner, WD
    Beer, T
    Chatta, G
    Shepard, R
    Unger, P
    Merica, EA
    Ette, E
    Harding, MW
    Dalton, WS
    CLINICAL CANCER RESEARCH, 1999, 5 : 3836S - 3836S
  • [2] Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer
    Rago, RP
    Einstein, A
    Lush, R
    Beer, TM
    Ko, YJ
    Henner, WD
    Bubley, G
    Merica, EA
    Garg, V
    Ette, E
    Harding, MW
    Dalton, WS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (04) : 297 - 305
  • [3] Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer
    Randall P. Rago
    Albert Einstein
    Richard Lush
    Tomasz M. Beer
    Yoo-Joung Ko
    W. David Henner
    Glenn Bubley
    Elizabeth A. Merica
    Varun Garg
    Ene Ette
    Matthew W. Harding
    William S. Dalton
    Cancer Chemotherapy and Pharmacology, 2003, 51 : 297 - 305
  • [4] A Phase II study of IncelTM (biricodar, VX-710) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel
    Toppmeyer, D
    Seidman, A
    Overmoyer, B
    Pollak, M
    Verma, S
    Russell, C
    Tkaczuk, K
    Del Prete, S
    Schwartz, G
    Harding, MW
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S322 - S322
  • [5] Safety and efficacy of the multidrug resistance inhibitor Incel (Biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel
    Toppmeyer, D
    Seidman, AD
    Pollak, M
    Russell, C
    Tkaczuk, K
    Verma, S
    Overmoyer, B
    Garg, V
    Ette, E
    Harding, MW
    Demetri, GD
    CLINICAL CANCER RESEARCH, 2002, 8 (03) : 670 - 678
  • [6] A Phase II study of IncelTM (biricodar, VX-710) plus paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.
    Seiden, M
    Swenerton, K
    Matulonis, U
    Rose, P
    Batist, G
    Verma, S
    Oza, A
    Popadiuk, C
    Bessette, P
    Angers, E
    Ette, E
    Harding, MW
    Charpentier, D
    CLINICAL CANCER RESEARCH, 1999, 5 : 3836S - 3836S
  • [7] A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy
    Seiden, MV
    Swenerton, KD
    Matulonis, U
    Campos, S
    Rose, P
    Batist, G
    Ette, E
    Garg, V
    Fuller, A
    Harding, MW
    Charpentier, D
    GYNECOLOGIC ONCOLOGY, 2002, 86 (03) : 302 - 310
  • [8] A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC).
    Rosenberg, JE
    Kelly, WK
    Michaelson, MD
    Wilding, G
    Hussain, M
    Gross, M
    Small, EJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 394S - 394S
  • [9] Randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane resistant (TR) hormone refractory prostate cancer (HRPC)
    Chowdhury, S.
    Burbridge, S.
    Harper, P. G.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (12) : 2064 - 2070
  • [10] A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Eigl, B. J.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345